Questions and answers on agonist pharmacology, receptor theory, drug mechanisms, and the science behind full agonists, partial agonists, and antagonists.
Posted by PharmStudentYr2 · 48 replies
A full agonist binds to and activates a receptor to produce the maximum possible response (Emax) that the receptor system is capable of—it has an intrinsic efficacy of 1.0. A partial agonist binds the same receptor but produces a submaximal response even at full receptor occupancy—its intrinsic efficacy is between 0 and 1. Critically, a partial agonist can act as a functional antagonist in the presence of a full agonist, competing for the same receptor while producing less effect. Buprenorphine is a clinically important example: it is a partial agonist at the mu-opioid receptor, providing pain relief and reducing withdrawal symptoms with a ceiling effect that limits respiratory depression compared to full agonists.
Posted by InverseAgonistQ · 41 replies
A neutral antagonist blocks agonist binding and has zero intrinsic efficacy—it produces no effect at a receptor with no constitutive activity. An inverse agonist also blocks agonist binding but additionally suppresses the receptor's constitutive (baseline) activity below the unstimulated level, producing an opposite effect to an agonist. This distinction is clinically relevant: H2 receptor inverse agonists like cimetidine and ranitidine actually decrease basal acid secretion rather than just blocking histamine-stimulated secretion. Distinguishing inverse agonists from neutral antagonists requires systems with measurable constitutive receptor activity.
Posted by DesensitizationMech · 36 replies
Receptor desensitization describes the reduced response to an agonist despite continued receptor occupancy. For G-protein coupled receptors (GPCRs), the classical mechanism involves G-protein coupled receptor kinases (GRKs) phosphorylating the activated receptor, followed by beta-arrestin binding, which sterically blocks G-protein coupling. This is followed by receptor internalization (endocytosis) and either recycling back to the membrane or lysosomal degradation (downregulation). In clinical practice, beta-agonist desensitization in asthma and opioid tolerance in pain management are major consequences of this molecular process.
Posted by AntagonismTypes · 44 replies
Competitive antagonists bind reversibly to the orthosteric site (the same binding site as the agonist) and can be overcome by increasing agonist concentration—they shift the agonist dose-response curve to the right but do not reduce the maximum response (Emax). Non-competitive antagonists bind to an allosteric site or bind irreversibly to the orthosteric site; they reduce the maximum achievable response and cannot be overcome by adding more agonist. On a log dose-response graph, competitive antagonism shifts the curve rightward while non-competitive antagonism flattens the curve.
Posted by OpioidPharmacology · 53 replies
The clinically important mu-opioid receptor agonists differ in potency, onset, duration, and receptor binding kinetics. Morphine has relatively slow onset and is the reference standard. Fentanyl is 80–100x more potent, with rapid onset due to high lipophilicity facilitating CNS penetration. Buprenorphine is a partial agonist with extremely high receptor affinity and slow dissociation, making it difficult to reverse with standard naloxone doses and giving it a 'ceiling' on respiratory depression. Methadone is a full agonist with unusually long half-life and additional NMDA receptor antagonism relevant to pain management.
Posted by BetaAgonistAsthma · 39 replies
Beta-2 adrenergic agonists bind to beta-2 receptors on bronchial smooth muscle, activating adenylyl cyclase via Gs protein coupling to increase cAMP, leading to smooth muscle relaxation and bronchodilation. Short-acting beta agonists (SABAs) like albuterol (salbutamol) have rapid onset and are used for acute symptom relief. Long-acting beta agonists (LABAs) like salmeterol and formoterol are used for maintenance treatment, typically in combination with inhaled corticosteroids. Prolonged LABA monotherapy without corticosteroids carries safety concerns including increased asthma mortality, per FDA black box warnings.
Posted by ReceptorReserveConcept · 28 replies
Receptor reserve (spare receptors) refers to the phenomenon where a full agonist can produce the maximum tissue response while occupying only a fraction of available receptors. This occurs because the downstream signaling cascade amplifies the receptor signal—even a small fraction of occupied receptors can saturate intracellular second messengers. Receptor reserve has important implications: it means the EC50 (concentration producing 50% of maximum effect) is lower than the Kd (dissociation constant), and partial agonists can appear as full agonists in tissues with large receptor reserves.
Posted by NaloxonePharmacology · 61 replies
Naloxone is a competitive opioid receptor antagonist with high affinity for mu, kappa, and delta opioid receptors. It displaces bound opioid agonists from receptors and blocks further agonist binding, rapidly reversing respiratory depression, sedation, and analgesia. Its onset of action is 2–5 minutes intravenously. Its short half-life (30–80 minutes) is shorter than most opioids, meaning repeated dosing or a continuous infusion may be necessary for long-acting opioids like methadone. Intranasal formulations (Narcan) and auto-injectors (Evzio) have been developed for community layperson use in overdose emergencies.
Posted by BiasedAgonismQuestion · 32 replies
Traditional agonism assumes a ligand activates all downstream signaling pathways of a receptor proportionally. Biased agonism (also called functional selectivity) describes ligands that preferentially activate one signaling pathway over another—for example, preferentially activating G-protein pathways while simultaneously biasing against beta-arrestin recruitment, or vice versa. This is pharmacologically significant because different pathways may mediate different therapeutic effects versus side effects. Research into G-protein biased opioid agonists aims to produce analgesia (G-protein pathway) while minimizing tolerance and respiratory depression (beta-arrestin pathway), though this hypothesis remains under active investigation.
Posted by BenzoDependence_Q · 45 replies
Benzodiazepines act as positive allosteric modulators (PAMs) at the GABA-A receptor, enhancing the effect of GABA without directly activating the receptor themselves—making them positive allosteric agonists from a functional perspective. Chronic use leads to downregulation and altered subunit composition of GABA-A receptors, reducing GABA-mediated inhibition over time. Clinically, this manifests as tolerance (requiring higher doses for the same effect) and physical dependence (abrupt discontinuation can cause life-threatening withdrawal seizures due to CNS hyperexcitability). Tapering benzodiazepine doses gradually—often over months—is required to safely discontinue chronic use.
Join thousands of members sharing knowledge and experiences.